tqb2934
mAbexperimentalBi-specific
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 31, 2023 (NCT05646758)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
CD3E agonist
- BCMABINDING AGENT
BCMA
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07266116 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2025 | Government of China |
| NCT07179679 | Phase 1 | Oct 31, 2025 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT05646758 | Phase 1 | Jan 31, 2023 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd | For profit | 2 | 2 | 1 | 2023 |
| Government of China | Government | 1 | 1 | 1 | 2025 |
2 organizations
Page 1 / 1